BioSpecifics Technologies Corp (BSTC) financial statements (2021 and earlier)

Company profile

Business Address 35 WILBUR ST
LYNBROOK, NY 11563
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 898159493321
Cash and cash equivalents 51375510
Short-term investments 846852442811
Receivables 19175434
Capitalized contract cost  0
Deferred costs   2111
Other undisclosed current assets 111100
Total current assets: 1099866553825
Noncurrent Assets
Operating lease, right-of-use asset 0
Long-term investments and receivables 1716441
Long-term investments 1716441
Intangible assets, net (including goodwill) 100000
Intangible assets, net (excluding goodwill) 100000
Deferred costs   1233
Other undisclosed noncurrent assets  02311
Total noncurrent assets: 1729976
TOTAL ASSETS: 12710075654631
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including: 121111
Accrued liabilities 020000
Employee-related liabilities 000000
Taxes payable 0 0   
Other undisclosed accounts payable and accrued liabilities 000100
Debt 0     
Deferred revenue and credits1100
Other undisclosed current liabilities 010000
Total current liabilities: 132211
Noncurrent Liabilities
Long-term debt and lease obligation 0     
Operating lease, liability 0
Liabilities, other than long-term debt 1 5600
Deferred revenue and credits5600
Deferred income tax liabilities 1
Total noncurrent liabilities: 1 5600
Total liabilities: 237811
Stockholders' equity
Stockholders' equity attributable to parent 1249868564530
Common stock 000000
Treasury stock, value (12)(11)(8)(7)(6)(4)
Additional paid in capital 393633333225
Retained earnings 977242311910
Total stockholders' equity: 1249868564530
TOTAL LIABILITIES AND EQUITY: 12710075654631

Income statement (P&L) ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenue, net27262314
Gross profit: 383327262314
Operating expenses (10)(10)(10)(9)(8)(8)
Other undisclosed operating income      1
Operating income: 28231817147
Nonoperating income 211000
Investment income, nonoperating 211000
Other nonoperating income (expense) (0)00000
Income from continuing operations before income taxes: 30251817157
Income tax expense (6)(5)(7)(6)(5)(2)
Net income available to common stockholders, diluted: 24201111105

Comprehensive Income ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net income: 24201111105
Comprehensive income, net of tax, attributable to parent: 24201111105

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: